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The application of genetics to human health is poised for dramatic expansions. The
draft sequencing of the human genome has already led to discoveries about some of the
genetic factors contributing to heart disease, diabetes, Parkinson’s disease, asthma, and other
common illnesses. Before 2010, people may be able to learn their genetic susceptibilities to
common disorders, allowing for design of individualized preventive medicine through life-style
changes, diet, and medical surveillance (I). We may be able to predict who will respond
effectively to a particular drug therapy and who will suffer side effects.
Public support for the Human Genome Project is based on its promise for improving
human health (2). However, this enthusiasm has been tempered by fear that information
about our genetic make-up will make us vulnerable to discrimination by insurance companies
and employers. Such fear, whether justified or not, has already had negative effects. A recent
study reported that about one-third of people expressed concern that genetic testing could
cause them to lose their health insurance, and these apprehensions caused some not to
participate in clinical research protocols (3). Another study found that fear about health
insurance discrimination was the most frequent reason for declining genetic counseling services
(4). Furthermore, surveys reflect the public’s distrust. In July 2000, Time magazine reported
that 75% of those surveyed would not want their insurers to know what diseases they are
predisposed to (5). Another survey found that 68% of people surveyed would not bill genetic
testing to their insurance company and 26% would use an alias to reduce the risk of insurance
discrimination (6). Clearly, there are many reasons why individuals might choose not to utilize
genetic services, but fear of discrimination should not serve as a barrier. Ironically, in
attempting over the last few years to prevent future discrimination, the unintended, but
unavoidable, consequence may be that fear is even more powerful.
What is the basis of this fear, and is it justified? Fear of misuse of genetic information
can readily be placed in the historical context of use of “genetic science” to achieve eugenic
ends in the United States and in Europe in the early 1900s (7). The United States used the
“genetic inferiority” of racial, ethnic, and economically disadvantaged groups as the rationale
for restricting their immigration into this country (8) and for passing state laws promoting
sterilization (9). Eugenics was the “scientific justification” for killing millions during the
Holocaust. During the early 1970s, African Americans who were carriers for the mutation
associated with sickle cell anemia were denied insurance coverage and charged higher rates
(10). In 2002, a case settlement required the Burlington Northern Santa Fe Railway Company

(BNSF) to pay up to @2.2 million to employees who were secretly tested for a genetic variation
purported to be associated with carpel tunnel syndrome.
Nevertheless, we have not seen widespread cases of genetic discrimination. Why?
First, we do not yet have widespread utilization of genetic services. Second, individuals may
not know or understand the underlying basis for an insurance or employment decision.
Furthermore, without clear legal remedies, healthy individuals with a genetic predisposition
may not want to risk loss of privacy for themselves and their families by going public with a
discrimination claim, an even greater risk than if the discrimination claim were based on race or
sex. Regardless of whether fear of genetic discrimination is based on perception or reality, we
must find a way to ensure public confidence in genetic research and use of genetic information.
To date, most of the attention has focused on genetic discrimination in the context of
health insurance and employment. Although adverse selection is a concern of the insurance
markets, we also recognize that individuals are fearful that once access to genetic information
is allowed in any context, it will be very difficult to limit its use. This concern is also at issue
when government, courts, and educational institutions have access to genetic information. Just
as significantly, individuals have expressed concern about the impact of sharing genetic
information on family relationships. However, there is no one public policy solution that can
address all these concerns, particularly without a better understanding of the complexity of the
issues. In the meantime, it seems prudent to try to focus our attention on the policy questions
raised when addressing genetic discrimination and privacy issues in health insurance and
employment (11).
If given access to genetic information, will the insurance industry and employers use it
appropriately? It is only reasonable to be concerned that health insurers and employers may
not fully understand the implications and limitations of genetic test results and the complex
relationships between the genotype and phenotype. Testing positive for a mutation is often
not deterministic; moreover, clinical validity and utility of most genetic tests have not yet been
tracked or fully understood. For example, in the BNSF case, the employer significantly
overestimated the value of a predictive genetic test.
Should we wait and see if the problem worsens? The promise of genetic technologies
lies in the future. We cannot judge the magnitude of the potential problem from our present
experience and data. Once use and sharing of genetic information enters databases, it will be
extremely hard to remove it or prevent disclosure. When the public appreciates the extent of
use of genetic information for nonmedical purposes, it will only further exacerbate fear of
discrimination and loss of privacy.
Do we need comprehensive federal legislation? Forty-four states have passed a variety
of genetic nondiscrimination and privacy laws. This patchwork of state laws, all of which have
restrictions and limitations, is insufficient to provide public reassurance. Furthermore, the
federal Employment Retirement and Income Security Act (ERISA) exempts self-funded plans
from state insurance laws. A large proportion of the population obtains insurance through such

plans and would not be protected. Although the Americans with Disabilities Act (ADA) arguably
protects individuals subjected to genetic discrimination in the workplace, the amount of
employment protection actually provided remains limited (12).
To date, there is no comprehensive federal legislation that addresses genetic
discrimination and privacy in both the insurance and employment contexts. We must establish
an effective legislative framework that reduces the threat of harm by restricting access to
genetic information and enforcing penalties for discrimination. Such legislation must create a
level playing field, where the rules are clear and fair for all. Because the advent of predictive
genetic testing does not create new illness costs (in fact, it could reduce them) and there is no
evidence that adverse selection operates in health insurance, there should be no significant
economic gain or loss to health insurers or employers if this information is simply declared off
limits.
Last year, Senate Majority Leader Tom Daschle stated that “Millions more Americans are likely
to go through what [the BNSF employees] and their families have gone through, unless
Congress passes a national ban against genetic discrimination.” (13). President Bush has also
stated “Just as we have addressed discrimination based on race, gender, and age, we must now
prevent discrimination based on genetic information.” (14).
If we act now to prevent genetic information and to prevent genetic discrimination, it is
out hope that it will not be too late to address the public’s fear and the threat of harm.
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